Nucala denied as non-formulary by Cigna?

Cigna's specific coverage criteria for nucala are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Nucala as "Non-Formulary" — and Your Appeal Options

Nucala (mepolizumab) may sit in a formulary tier that requires prior authorization or step therapy, or may be excluded from your specific Cigna plan's formulary entirely. A non-formulary denial does not mean the drug is medically inappropriate — it means your plan's benefit design does not automatically cover it. There are two parallel paths: a formulary exception (medical-necessity exception) and a standard internal appeal.

Formulary exceptions are available under ACA regulations and most plan documents when a covered drug in the same class is contraindicated, has failed, or is otherwise clinically inappropriate for the specific patient. Given that Nucala has a distinct mechanism targeting IL-5 and that patients vary in their response to available alternatives, this is a realistic exception path.

## Your Federal Appeal Rights

• Formulary exception request: File simultaneously with or before the internal appeal. Document why no formulary alternative is clinically appropriate.
• Internal appeal (ACA §2719 / ERISA §503): Full-and-fair review. File within the deadline on your denial notice.
• External review: Available after internal remedies are exhausted, generally within approximately four months of a final adverse determination.
• Expedited review: Available when asthma severity makes delay medically inappropriate.

## Concrete Appeal Steps

1. Identify which drugs are on Cigna's formulary for severe eosinophilic asthma — obtain the current formulary list. 2. Have the prescriber document why each formulary alternative is clinically inappropriate or has already failed. 3. Submit a formulary exception request AND a formal internal appeal with supporting clinical documentation. 4. If exception is denied, escalate to external review.

## Documentation to Gather

• Diagnosis confirmation: Confirmed severe eosinophilic asthma (or applicable indication) with specialist chart notes.
• Formulary alternative trial history: If other biologics were tried, document dates, clinical response, and reason for discontinuation.
• Clinical reasoning for Nucala specifically: Prescriber's explanation of why this agent is appropriate for this patient.
• Clinical severity: Exacerbation records, hospitalizations, oral corticosteroid burden, pulmonary function trends.
• Prescriber medical-necessity letter: Addresses each formulary alternative and explains why Nucala is the clinically appropriate choice.

## Criteria-Mapping Structure

Review Cigna's formulary exception criteria alongside Nucala's FDA-approved prescribing label. For each formulary alternative Cigna might propose, document either that it was tried and failed (with chart dates and outcomes) or that there is a documented clinical reason it is not appropriate for this patient. Reference the applicable asthma or eosinophilic disease guideline organization generically to support the prescriber's selection rationale.